Clonidine and Gilles de la Tourette's syndrome: Double-blind study using objective rating methods

Authors

  • Dr. Christopher G. Goetz MD,

    Corresponding author
    1. Department of Neurological Sciences, Rush University, Rush-Presbyterian–St. Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612
    • Department of Neurological Sciences, Rush University, Rush-Presbyterian–St. Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612
    Search for more papers by this author
  • Caroline M. Tanner MD,

    1. Department of Neurological Sciences, Rush University, Rush-Presbyterian–St. Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612
    Search for more papers by this author
  • Robert S. Wilson PhD,

    1. Department of Psychology and Social Sciences, Rush University, Rush-Presbyterian–St. Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612
    Search for more papers by this author
  • V. Carroll Susan MS,

    1. Department of Neurological Sciences, Rush University, Rush-Presbyterian–St. Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612
    Search for more papers by this author
  • Peter G. Como PhD,

    1. Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642
    Search for more papers by this author
  • Kathleen M. Shannon MD

    1. Department of Neurological Sciences, Rush University, Rush-Presbyterian–St. Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612
    Search for more papers by this author

Abstract

Clonidine has been suggested to be effective in Gilles de la Tourette's syndrome (GTS), but no double-blind study has ever evaluated its effects using objective measures. Thirty patients with GTS completed a 6-month placebo-controlled crossover study of the effectiveness of clonidine. Videotapes were obtained at each 3-week visit and were evaluated randomly at the end of the study for distribution, frequency, and severity of motor and vocal tics. Quantifiable psychometric examinations were performed as well. The use of clonidine did not significantly (p < 0.05) reduce motor tics, vocalizations, or behavior. The effect of a low dose (0.0075 mg/kg/day) was no different from that of a high dose (0.015 mg/kg/day); children's responses were no different from adults'; and those also receiving neuroleptic agents showed the same lack of efficacy as seen in patients on no other medication. Dosing schedule did not affect the objective ratings; scores from clonidine given twice a day were equivalent to those for three times a day.

Ancillary